Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical products company Taro Pharmaceutical Industries has earned a respected four-star ranking.
With that in mind, let's take a closer look at Taro and see what CAPS investors are saying about the stock right now.
Haifa Bay, Israel (1959)
Interim CEO James Kedrowski
Trailing-12-Month Operating Margin
$479.1 million / $28.3 million
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 92% of the 50 members who have rated Taro believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, All-Star DrGoldin, succinctly summed up the Taro bull case for our community: "What's not to like? Margins and returns at the high end of the industry, with nothing but consistent growth for the future. All this at a modest p/e (however you wish to calculate it). And clean sheets!"
If you want market-topping returns, you need to put together the best portfolio you can. Of course, despite its four-star rating, Taro may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Taro Pharmaceutical Is Poised to Keep Popping originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.